CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Researchers at the University of Chicago have developed a "universal" chimeric antigen receptor (CAR) platform that offers enhanced safety, adaptability, and the potential to overcome long-standing ...

Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with ...

Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy ...

The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...

Universal CAR T cells produce rapid remissions and enable allogeneic stem cell transplants in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.

Chimeric antigen receptor (CAR) T-cell therapy has shown efficacy in blood cancers — with six CAR T-cell products now approved by the US Food and Drug Administration (FDA) to treat six hematologic ...

Cold Spring Harbor Laboratory researchers reveal a groundbreaking approach using CAR T-cell therapy to rejuvenate aging ...

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys cancer cells for days without tiring. USC biomedical engineers have made ...

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor ...